MX2021008305A - Anticuerpos anti-cd40 para el uso en el tratamiento de hidradenitis supurativa. - Google Patents
Anticuerpos anti-cd40 para el uso en el tratamiento de hidradenitis supurativa.Info
- Publication number
- MX2021008305A MX2021008305A MX2021008305A MX2021008305A MX2021008305A MX 2021008305 A MX2021008305 A MX 2021008305A MX 2021008305 A MX2021008305 A MX 2021008305A MX 2021008305 A MX2021008305 A MX 2021008305A MX 2021008305 A MX2021008305 A MX 2021008305A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- treatment
- hidradenitis suppurativa
- suppurativa
- hidradenitis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19151461 | 2019-01-11 | ||
| PCT/IB2020/050132 WO2020144605A1 (en) | 2019-01-11 | 2020-01-09 | Anti-cd40 antibodies for use in treatment of hidradenitis suppurativa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021008305A true MX2021008305A (es) | 2021-08-24 |
Family
ID=65019425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021008305A MX2021008305A (es) | 2019-01-11 | 2020-01-09 | Anticuerpos anti-cd40 para el uso en el tratamiento de hidradenitis supurativa. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12435150B2 (enExample) |
| EP (1) | EP3908310A1 (enExample) |
| JP (3) | JP2021506953A (enExample) |
| KR (1) | KR20210114964A (enExample) |
| CN (1) | CN113271964A (enExample) |
| AU (1) | AU2020205839A1 (enExample) |
| BR (1) | BR112021013174A2 (enExample) |
| CA (1) | CA3125886A1 (enExample) |
| CL (1) | CL2021001829A1 (enExample) |
| IL (1) | IL284338A (enExample) |
| MX (1) | MX2021008305A (enExample) |
| TW (1) | TW202033558A (enExample) |
| WO (1) | WO2020144605A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022061061A1 (en) * | 2020-09-21 | 2022-03-24 | Boehringer Ingelheim International Gmbh | Use of anti-cd40 antibodies for treatment of inflammatory conditions |
| HRP20250696T1 (hr) | 2021-01-28 | 2025-08-01 | Regeneron Pharmaceuticals, Inc. | Sastavi i postupci za liječenje sindroma oslobađanja citokina |
| WO2024261192A1 (en) * | 2023-06-20 | 2024-12-26 | Kymab Limited | Use of ox40 and ox40l modulators to treat hidradenitis suppurativa |
| WO2025147499A1 (en) * | 2024-01-03 | 2025-07-10 | Abbvie Inc. | Lutikizumab for use in a treatment of hidradenitis suppurativa |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| US20250277048A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
| WO2025235683A1 (en) | 2024-05-07 | 2025-11-13 | Eledon Pharmaceuticals, Inc. | Methods and compositions for prevention of transplant rejection |
| WO2025235670A1 (en) | 2024-05-07 | 2025-11-13 | Eledon Pharmaceuticals, Inc. | Use of anti-cd40 ligand antibodies for immunosuppression in islet cell transplantation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US20050136055A1 (en) | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
| RU2377254C2 (ru) | 2003-12-25 | 2009-12-27 | Кирин Фарма Кабусики Кайся | Мутанты анти-cd40 антитела |
| EP1854810A1 (en) | 2006-05-09 | 2007-11-14 | PanGenetics B.V. | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
| RS60612B1 (sr) | 2010-03-31 | 2020-08-31 | Boehringer Ingelheim Int | Anti-cd40 antitela |
| AR083847A1 (es) * | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| ES2711100T3 (es) | 2011-03-07 | 2019-04-30 | Celgene Corp | Métodos para tratar enfermedades usando compuestos isoindolina |
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| UY36692A (es) | 2015-05-29 | 2016-12-30 | Abbvie Inc | Anticuerpos anti-cd40 y usos de los mismos |
| RU2020117156A (ru) * | 2017-12-01 | 2022-01-04 | Эббви Инк. | Конъюгаты анти-cd40 антитела и лекарственного средства |
-
2020
- 2020-01-09 BR BR112021013174A patent/BR112021013174A2/pt not_active IP Right Cessation
- 2020-01-09 US US17/422,075 patent/US12435150B2/en active Active
- 2020-01-09 EP EP20701367.3A patent/EP3908310A1/en active Pending
- 2020-01-09 CA CA3125886A patent/CA3125886A1/en active Pending
- 2020-01-09 CN CN202080008145.XA patent/CN113271964A/zh active Pending
- 2020-01-09 TW TW109100800A patent/TW202033558A/zh unknown
- 2020-01-09 WO PCT/IB2020/050132 patent/WO2020144605A1/en not_active Ceased
- 2020-01-09 JP JP2020539848A patent/JP2021506953A/ja active Pending
- 2020-01-09 AU AU2020205839A patent/AU2020205839A1/en not_active Abandoned
- 2020-01-09 MX MX2021008305A patent/MX2021008305A/es unknown
- 2020-01-09 KR KR1020217024671A patent/KR20210114964A/ko not_active Withdrawn
-
2021
- 2021-06-23 IL IL284338A patent/IL284338A/en unknown
- 2021-07-01 JP JP2021109796A patent/JP7558900B2/ja active Active
- 2021-07-08 CL CL2021001829A patent/CL2021001829A1/es unknown
-
2024
- 2024-09-18 JP JP2024161056A patent/JP2024178278A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021013174A2 (pt) | 2021-11-03 |
| US20220098315A1 (en) | 2022-03-31 |
| US12435150B2 (en) | 2025-10-07 |
| AU2020205839A1 (en) | 2021-06-03 |
| CN113271964A (zh) | 2021-08-17 |
| JP2021506953A (ja) | 2021-02-22 |
| CA3125886A1 (en) | 2020-07-16 |
| JP2021181439A (ja) | 2021-11-25 |
| JP7558900B2 (ja) | 2024-10-01 |
| IL284338A (en) | 2021-08-31 |
| WO2020144605A1 (en) | 2020-07-16 |
| CL2021001829A1 (es) | 2022-04-22 |
| TW202033558A (zh) | 2020-09-16 |
| KR20210114964A (ko) | 2021-09-24 |
| EP3908310A1 (en) | 2021-11-17 |
| JP2024178278A (ja) | 2024-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021008305A (es) | Anticuerpos anti-cd40 para el uso en el tratamiento de hidradenitis supurativa. | |
| BR112017007003A2 (pt) | método para modulação de atividade de células imunes induzidas por car | |
| MX2020004411A (es) | Anticuerpos anti-cd40 para usarse en el tratamiento del sindrome de sjogren. | |
| CL2019001553A1 (es) | Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador. | |
| PE20150223A1 (es) | Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| MX2022015631A (es) | Anticuerpos anti-cd40 humanizados y usos de los mismos. | |
| MX2024000348A (es) | Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica. | |
| AR097481A1 (es) | Cocristales energéticos para el tratamiento de una formación subterránea | |
| MX2017014191A (es) | Metodos de tratamiento de una enfermedad neurodegenerativa. | |
| BR112017005598A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
| MX2017011834A (es) | Macrociclos peptidomimeticos y usos de los mismos. | |
| MX2017000142A (es) | Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica. | |
| CL2016000436A1 (es) | Método para el tratamiento de la enfermedad fibrótica | |
| ECSP18031122A (es) | Uso de trientina para el suministro de cobre a un tejido isquémico | |
| SG10201804034QA (en) | Methods for treating hypotension | |
| AR101449A1 (es) | Inhibidores de myh7b y usos de los mismos | |
| ES2684856R1 (es) | Método para producir una matriz de tejido descelularizado | |
| MX2016016407A (es) | Composiciones biofotonicas termoestables y usos de las mismas. | |
| CL2021002889A1 (es) | Anticuerpos anti-cd40 para uso en el tratamiento de la t1dm y la insulitis | |
| MX2015012513A (es) | Reactor de esterilizacion y metodo. | |
| BR112017011513A2 (pt) | tratamento de condições oculares usando células progenitoras | |
| MX386151B (es) | Uso de tricostatina a (tsa) en el tratamiento del mieloma múltiple. | |
| CL2019003161A1 (es) | Métodos de tratamiento selectivo del asma usando antagonistas de il-17. | |
| MX2019015273A (es) | Moduladores de alfa-sinucleinca. |